10/18/2024

Janusmed sex and gender

Janusmed sex and gender – ranitidine

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Ranitidine

Ranitidine

Class : A

Show all info

Print

Contact us

  1. Abad-Santos F, Carcas AJ, Guerra P, Govantes C, Montuenga C, Gómez E et al. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J Clin Pharmacol. 1996;36:748-51.

  2. Flores Pérez J, Juárez Olguín H, Flores Pérez C, Pérez Guillé G, Guillé Pérez A, Camacho Vieyra A et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int. 2003;20:485-94.

  3. Zantac (ranitidin). Summary of Product Characteristics. Swedish Medical Products Ageny; 2015.

  4. Sue SO, Dawson DM, Brown JA, Wood DR, Kleoudis CS. Effectiveness of ranitidine 150 mg at bedtime as maintenance therapy for healed gastric ulcers. Clin Ther. 1996;18:1175-83.

  5. Takemoto T, Sakaki N, Tsuneoka K, Namiki M, Ishikawa M, Oshiba S. Clinical usefulness of ranitidine in giant gastric ulcer. J Clin Gastroenterol. 1984;6:413-7.

  6. Lee FI, Samloff IM, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985;1:1299-302.

  7. Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986;91:1198-205.

  8. Penston JG, Dixon JS, Boyd EJ, Wormsley KG. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther. 1993;7:259-65.

  9. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]

  1. Abad-Santos F, Carcas AJ, Guerra P, Govantes C, Montuenga C, Gómez E et al. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J Clin Pharmacol. 1996;36:748-51.
  2. Flores Pérez J, Juárez Olguín H, Flores Pérez C, Pérez Guillé G, Guillé Pérez A, Camacho Vieyra A et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int. 2003;20:485-94.
  3. Zantac (ranitidin). Summary of Product Characteristics. Swedish Medical Products Ageny; 2015.
  4. Sue SO, Dawson DM, Brown JA, Wood DR, Kleoudis CS. Effectiveness of ranitidine 150 mg at bedtime as maintenance therapy for healed gastric ulcers. Clin Ther. 1996;18:1175-83.
  5. Takemoto T, Sakaki N, Tsuneoka K, Namiki M, Ishikawa M, Oshiba S. Clinical usefulness of ranitidine in giant gastric ulcer. J Clin Gastroenterol. 1984;6:413-7.
  6. Lee FI, Samloff IM, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985;1:1299-302.
  7. Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986;91:1198-205.
  8. Penston JG, Dixon JS, Boyd EJ, Wormsley KG. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther. 1993;7:259-65.
  9. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]